Compare Novo Nordisk A/S (NVO) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Quantumscape Corp — how do they compare? Novo Nordisk A/S trades at $38.41 (market cap $165.31B), while Quantumscape Corp trades at $4.6 (market cap $2.82B). The key difference: Novo Nordisk A/S is far larger — about 58.6× Quantumscape Corp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Quantumscape Corp for 37 Days on average.
| NVO | QS | |
|---|---|---|
Market Cap | $165.31B | $2.82B |
Volume | 11,432,838 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $18.44 |
52-Week Low | $35.29 | $4.52 |
Typical Hold Time | 116 Days | 37 Days |
Enterprise Value | $179.56B | $2.03B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
QuantumScape (QS) trades at $4.52, down 2.8% on the day, reflecting ongoing investor skepticism about the solid-state battery developer's path to commercialization. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamental challenges persist with zero revenue, negative EBITDA of -$358.25M (2025), and consecutive quarterly losses. Recent news highlights commercialization delays and insider selling, though the company continues ramping pilot production lines for automotive and new market applications.
The outlook remains high-risk with commercialization not expected until 2029, creating significant execution and competitive threats. While the consensus price target of $10.35 suggests potential upside from current levels, analyst sentiment is cautious with 73% hold ratings. Investment opportunity exists only for speculative investors comfortable with pre-revenue developmental stage risks and extended timelines to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
